4 • Jan–Mar 2022 • Vol LXI • No. 3 Research at Himalaya Efficacy of Evecare forte™ in the Management of Polycystic Ovarian Syndrome An excerpt of the preclinical study conducted by Azeemuddin M et al published in Advances in Pharmacological Sciences is featured here. A study was conducted to evaluate the efficacy of Evecare forte on testosterone propionate (TP)–induced polycystic ovarian syndrome (PCOS) in rats. Thirty female rats were considered for the study; they were divided into 3 groups of 10 each. Group 1 served as normal control; group 2 served as positive control and was administered TP; and group 3 served as test group and was administered TP along with Evecare forte at a dose of 100 mg/kg po, for 60 days. After the 60-day study period, all the 3 groups were evaluated for the following parameters: glucose intolerance, weight of the ovaries, estrus cycle, serum testosterone level, and histoarchitecture of the ovaries. GLUT4 expression assay was done to evaluate the effect of Evecare forte on insulin resistance. Results showed that treatment with Evecare forte reduced body weight, glucose and testosterone levels, and weight of the ovaries, increased GLUT4 expression, and normalized irregular estrus cycle. Furthermore, Evecare forte caused a decrease in cystic follicle formation and atrophic changes. Evecare forte resulted in an overall recovery in the histoarchitecture of the ovaries. Thus, Evecare forte reverses the pathophysiologic changes such as metabolic dysfunction and reproductive impairment associated with PCOS. The herbs present in Evecare forte exhibit beneficial effects on the female reproductive system, proving the efficacy of Evecare forte in the management of PCOS. Evecare forte™ (LIQUID, TABLET) For the effective management of PCOS Evecare forte is a polyherbal, nonhormonal menstrual modulator indicated for the comprehensive management of polycystic ovarian syndrome (PCOS). Evecare forte helps regularize the endogenous hormonal status, helps correct the cyclical rhythm, and helps reduce the number of abnormal ovarian follicles. It improves ovulatory function and other metabolic derangements associated with insulin resistance due to its insulin-sensitizing activity. Evecare forte helps regularize menstrual cycles and helps correct symptoms of hyperandrogenism such as hirsutism and hyperpigmentation. Furthermore, it improves chances of fertility and also helps reduce mood swings, anxiety, and depression associated with PCOS. Preclinical Evidence An excerpt of the clinical study conducted by Ahalya S (yet to be published) is featured here. Forty women (aged 18–45 y) with symptoms of PCOS, such as irregular menstrual cycles, weight gain, biochemical/clinical hyperandrogenemia, and hirsutism were advised Evecare forte liquid at a dosage of 20 mL, BID, for 3 months. Clinical symptoms and physical, hematological, biochemical, and hormonal parameters were assessed in all the women, at entry and at each follow-up (months 1, 2, and 3). Ultrasonography was performed at the beginning and at the end of the study. There was a significant reduction in the duration of menstruation and the intermenstrual interval in all the women (Table). There was also a reduction in the testosterone and the luteinizing hormone levels and the number and size of ovarian follicles as evaluated through ultrasonography. There were no significant adverse effects either observed or reported during the study. Thus, Evecare forte liquid is an effective nonhormonal menstrual modulator. It helps regularize endogenous hormonal secretion, correct the cyclical rhythm, and relieve the symptoms of PCOS. Table. Effect of Evecare forte Liquid on Menstrual Symptoms Parameter At Entry Month 1 Month 2 Month 3 P Value No. of Days of Menstruation 5.31 ± 4.52 3.62 ± 0.96 3.00 ± 0.82 2.69 ± 0.75 aP < .035 Intermenstrual Interval, d 44.88 ± 19.72 44.43 ± 28.2 35.25 ± 22.19 27.5 ± 1.69 aP < .0299 Statistical test: ANOVA, Tukey’s multiple comparison test, Friedman’s test, and Dunn’s multiple comparison test. Significance was fixed at < .05. Values are given as mean ± SD. aCompared with at-entry values. Clinical Evidence
RkJQdWJsaXNoZXIy OTU3ODk=